JOGO Health

JOGO Health

Early Stage

Stroke, chronic pain & incontinence treatment via telehealth with wearables & AI

Stroke, chronic pain & incontinence treatment via telehealth with wearables & AI


Raised to Date: Raised: $2,301,695

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Convertible Note



SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap




Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Bridgewater, New Jersey

Business Type


JOGO Health, with a valuation cap of $20 million, is raising crowdfunding on Wefunder. The company makes wireless and wearable sensors that provide treatment for neuromuscular conditions like stroke and break the pain-anxiety muscle tension cycle. The device is connected to a patent-protected mobile app that provides treatment protocols and games that work on neuromuscular reeducation, movement coordination, and leveraging neuroplasticity. Sanjai Murali and Siva Nadarajah founded JOGO Health in June 2010. The proceeds of the current crowdfunding campaign, with a minimum raise of $500,000 and a maximum raise of $3,500,000, will be used to complete Chronic Lower Back Pain clinical trial at Harvard Brigham and Women’s Hospital, buy inventory, set up a patient support call center, and expand on the current success in India. JOGO Health treats over twenty neuromuscular conditions and has already treated more than 2,000 patients.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 08/09/2021
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
JOGO Health 05/21/2024 Wefunder $37,000,000 $674,818 Equity - Preferred Active RegCF
JOGO Health 11/04/2021 Wefunder $20,000,000 $2,301,695 Convertible Note Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article


Neuromuscular disorder is an umbrella category for a range of conditions that affect the nerves that control voluntary muscle movements. Many of these conditions have no cure, but there are treatments that can slow progression and improve quality of life. However, these treatments often come with limitations and unpleasant side effects.  

JOGO Health aims to treat neuromuscular disorders without the side effects. The telehealth company uses an app and wearable technology to leverage artificial intelligence and virtual reality to treat neuromuscular conditions. Instead of providing medicines, JOGO Health’s technology gives patients treatment protocols and games that can be adapted for muscle relaxation, movement combination, and neuromuscular symptom reduction. The product helps patients recover by rewiring their central nervous system and recruiting muscles to help treat their conditions. This approach can reduce the side effects of medicines and potentially address the root cause of the disorders. 

JOGO Health’s current raise on Wefunder has been rated a Neutral Deal by the KingsCrowd Investment Team.

Next Section: Price


JOGO Health is raising on a convertible note with a valuation cap of $20 million, discount rate of 20%, and an interest rate of 5%. For the 2020 fiscal year, the company had revenues of $65,390 in India and $0 in the United States. Based on the revenues generated in India, the company has a revenue multiple of 306 times, which is significantly higher than the healthcare industry average (which ranges from three times to six times). The valuation is unreasonably high for a company that hasn’t fully launched its products in the US. Thus, JOGO Health receives a low price score.

Next Section: Market


JOGO Health targets the US and Indian telehealth markets, both of which have high potential. COVID-19 triggered an increase in telehealth visits, and it is likely this trend could outlast the pandemic. The US telehealth market is worth $12.8 billion with a fast growth rate of 28%. It is expected to reach $43 billion by 2026. India’s telehealth market is growing at a rate of 39.6% and is expected to reach $10.6 billion by 2025. 

Granted, only a fraction of the total market will focus on treatment for neuromuscular disorders. But in such a massive and fast-growing market, JOGO Health has many opportunities to succeed. Additionally, JOGO Health uses business-to-business and business-to-consumer distribution models, which creates even more opportunities for the company to establish itself in the market. Given the market’s large size, high growth rate, and promising potential, JOGO Health’s market score is very strong.

Next Section: Team


JOGO Health co-founder and president Siva Nadarajah has more than 20 years of clinical and safety experience in the pharmaceutical industry. Nadarajah also has exit experience in the technology and healthcare field. His previous venture, Semantelli — an AI-based drug safety detection and social media analytics platform — was acquired by IQVIA, one of the world’s leading clinical research organizations. Such leadership experience, especially in the health field, should contribute significantly to the development of JOGO Health. Co-founder and CEO Sanjai Murali has experience in development and marketing technology solutions. Murali has served in leadership positions at AT&T, FedEX, and Velankani, which are all valuable experiences for the growth of JOGO Health. 

The rest of the JOGO Health team is composed of skilled professionals, including clinical researchers in various neuromuscular disease fields, engineers, and a large medical advisory board. Chief Scientific Officer Gary Krasilovsky has been a clinician and researcher for more than 30 years. He also worked as a senior physical therapist at New York University Rusk Institute for Rehabilitation Medicine. Head of Commercial Strategy Shanmuga Priyan has more than two decades of healthcare operating experience in Asia — specifically in the South Asian markets, which will prove valuable as the company targets Indian markets. The team also has other researchers with a variety of expertise, including urogynecology and rehabilitation. Additionally, JOGO Health’s advisory board includes professors from the Yale School of Medicine and Harvard Medical School. The team and board members are strong indicators of the technical and operational success of JOGO Health. So overall, JOGO Health receives a strong team score.

Next Section: Differentiators


One of JOGO Health’s competitors is Hinge Health, which has received more than $400 million in funding. Hinge Health has partnered with more than 500 employees and health plans with big companies such as Philips and Tyson. Another top competitor is Kaia Health, which has more than 450,000 users around the world. Both Hinge Health and Kaia Health offer digital musculoskeletal therapy and symptom relief solutions, but only Hinge Health incorporates a wearable device. 

JOGO Health has some advantages over the competition. For one, Hinge Health and Kaia Health mainly focus on musculoskeletal care, while JOGO Health’s method has a broader focus. JOGO Health’s product can treat body pains and address pelvic health and cerebral palsy. JOGO Health’s product is also patent-protected, which makes it defensible. And the product is already FDA-cleared. FDA clearance is typically a massive hurdle for early-stage companies, so this is a positive signal for JOGO Health’s growth. JOGO Health also has a wider market than companies that operate only in the US, and its low capital intensity model will help its production scale in both countries. 

JOGO Health’s product has a unique and diverse use, it’s attacking a large market, and it has product defensibility. As such, JOGO Health receives a strong differentiation score.

Next Section: Performance


JOGO Health has achieved several milestones over the past two years. The company initially focused on the South Asia market and has been gaining traction in India. By March 2021, the company signed with 20 hospitals in India and treated 2,000 patients. In December 2020, the company began a study for chronic back pain at Harvard. By June 2021, the study reached 50% recruitment, and the company signed contracts with two clinics in New York City. While it is still uncertain how the product will be received in the US, its performance thus far in Asian markets should give investors confidence. 

According to the company’s website, the current product, JOGO-Gx, is the first product to be commercialized. The company plans to develop nine more generations of JOGOs in the future to address even more health conditions, including cancer pain, chronic fatigue syndrome and migraines. The company has already raised more than $3 million on Wefunder and generated around $65,000 revenue in India in 2020. So overall, JOGO Health receives an above-average performance score.

Next Section: Risks


There is some risk associated with an investment in JOGO Health. Several factors contribute to the elevated time risk. First of all, any healthcare technology must overcome regulatory hurdles, which take time to tackle. Additionally, JOGO Health needs to credential with insurance providers, which can take anywhere from two to four months. Although the company has already started the process, delays are expected due to the pandemic.

JOGO Health also comes with product risk. Initial tests seemed to produce good results, and the company has been successful in India. But it’s uncertain how effective and accepted its product will be in the US. 

The market also presents minor risk. Telehealth is a fast-growing industry in both the US and India. A large number of new companies enter the market each year, so JOGO Health will likely have more intense competition in the future. Although JOGO Health’s product is quite distinguishable from some established competitors, such as Kaia Health, competitors might develop new or similar products and capture some of JOGO Health’s target customers.

Next Section: Bearish Outlook

Bearish Outlook

JOGO Health’s biggest issue is its product development and market acceptance. For one, it is unclear how the product will be accepted in the US market. In addition, the company has claimed that its technology could treat many different types of neuromuscular disorders. However, judging from the company’s website, the product is still in early-stage development, and JOGO Health has only treated a small number of patients so far. Hence, it remains to be seen whether the product will be as powerful as the company claims. 

Furthermore, only one of its products has been cleared by the FDA. The registration and approval process typically takes months, if not longer. JOGO Health will face many regulatory hurdles in its path to growth. Finally, there are many competitors in the space, including Hinge Health and Kaia Health — both of which are well established and have received millions in funding.

Next Section: Bullish Outlook

Bullish Outlook

JOGO Health’s two target markets, the US and Indian telehealth markets, both have staggeringly high growth rates. Demand for telehealth services is unlikely to go away, even after the pandemic recedes. And considering an increased public openness to new, alternative, versions of medical treatment, a growing number of patients and clinics may start to adopt new technologies like JOGO Health’s. 

JOGO Health also has a strong team behind it. The entire team and advisory board consists of experts in various fields with decades of combined experience. Co-founder Sanjai Murali brings valuable leadership experience from AT&T, FedEX, and Velankani. President Siva Nadarajah sold his previous company to a clinical research giant, which indicates strong entrepreneurial skills. 

Next Section: Executive Summary

Executive Summary

JOGO Health uses wearable technology, artificial intelligence, and virtual reality to treat neuromuscular conditions. The company’s device is connected to a patent-protected mobile app that provides treatment protocols and games that work on neuromuscular reeducation and movement coordination, leveraging the brain’s ability to rewire itself. 

JOGO Health’s performance thus far has proven impressive. The team has treated more than 2,000 patients, built partnerships with hospitals in both India and the US and begun generating revenue. JOGO Health also has a strong team, with one founder having a previous exit in the industry. The team has also put together a stacked advisory board with members from top tier research universities. The company’s product is fairly differentiated, which should help it compete. Finally, the team already holds a patent for its technology and has obtained FDA clearance.

However, JOGO Health is still quite early-stage and in a competitive market with a steep valuation. Competitors like Hinge Health and Kaia Health already have massive amounts of funding. The company will also have to face regulatory and adoption hurdles with each iteration of or branch off of its product. And at this point, its product has been launched only in the Southeast Asian markets. Therefore, JOGO Health has been rated a Neutral Deal by the KingsCrowd investment team.  

For questions regarding the KingsCrowd staff pick or ratings for this company, please reach out to

Analysis written by Bridget Sheng.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
JOGO Health on Wefunder 2021
Platform: Wefunder
Security Type: Convertible Note
Valuation: $20,000,000

Follow company

Follow JOGO Health on Wefunder 2021

Buy JOGO Health's Deal Report

Warning: according to the close date for this deal, JOGO Health may no longer be accepting investments.

JOGO Health Deal Report

Get KingsCrowd’s comprehensive report on JOGO Health including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether JOGO Health is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the JOGO Health deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge